ReviewPediatric nephrology (Berlin, Germany)2019
Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).
Review in Pediatric nephrology (Berlin, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Eculizumab in severe pediatric STEC-HUS and its impact on neurological prognosis-a systematic review and meta-analysis.European journal of pediatrics · 2025Pooled it
- Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review.Renal failure · 2021Pooled it
- Erythropoietin in children with hemolytic uremic syndrome: a pilot randomized controlled trial.Pediatric nephrology (Berlin, Germany) · 2022Trial
- Beyond the kidney: prevalence of extrarenal complications and their long-term sequelae in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Observational
- Behavior of Shiga Toxin-ProducingFoods (Basel, Switzerland) · 2026Article
- Acute neurologic clinical manifestations and outcomes in children with thrombotic microangiopathies in paediatric intensive care units.European journal of pediatrics · 2026Observational
- Incidence and severity of extrarenal manifestations and outcomes in pediatric hemolytic uremic syndrome: a retrospective cohort study.Pediatric nephrology (Berlin, Germany) · 2026Article
- Article
- Pericardial effusion in pediatric Shiga toxin-producing E. coli hemolytic uremic syndrome: a French multicentre study.Pediatric nephrology (Berlin, Germany) · 2026Article
- Genomic epidemiology reveals statewide dispersal of clinical Shiga toxin-producingMicrobiology spectrum · 2026Article
- Case Report: Complement-mediated thrombotic microangiopathy masquerading as a pancreatic mass.Frontiers in medicine · 2026Article
- Urgent Colectomy for Colonic Necrosis Following Shiga Toxin-ProducingSurgical case reports · 2026Article
- Eliglustat prevents acute kidney injury caused by Shiga toxin 2 in lethal and sublethal rat models of hemolytic uremic syndrome.Frontiers in pharmacology · 2026Article
- Liver Involvement in Children with Hemolytic Uremic Syndrome: Clinical Significance and Prognostic Value.Children (Basel, Switzerland) · 2025Article
- Shiga Toxin-ProducingKidney international reports · 2025Article
- Bilateral tractional retinal detachments complicating hemolytic-uremic syndrome.American journal of ophthalmology case reports · 2025Article
- A presentation of posterior reversible encephalopathy syndrome after heart transplantation: a case report and review of literature.Journal of medical case reports · 2025Review
- Role of INM004 Shiga-toxin antibodies in treatment of STEC-HUS.Pediatric nephrology (Berlin, Germany) · 2025Article
- Shiga toxin-producing Escherichia coli infection-related acute encephalopathy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- The role of the complement system in Shiga toxin-associated hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemolytic uremic syndrome is commonly caused by Shiga toxin-producing Escherichia coli (STEC). Up to 15% of individuals with STEC-associated hemorrhagic diarrhea develop hemolytic uremic syndrome (STEC HUS). Hemolytic uremic syndrome (HUS) is a disorder comprising of thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury. The kidney is the most commonly affected organ and approximately half of the affected patients require dialysis. Other organ systems can also be affected including the central nervous system and the gastrointestinal, cardiac, and musculoskeletal systems. Neurological complications include altered mental status, seizures, stroke, and coma. Gastrointestinal manifestations may present as hemorrhagic colitis, bowel ischemia/necrosis, and perforation. Pancreatitis and pancreatic beta cell dysfunction resulting in both acute and chronic insulin dependant diabetes mellitus can occur. Thrombotic microangiopathy (TMA) in cardiac microvasculature and troponin elevation has been reported, and musculoskeletal involvement manifesting as rhabdomyolysis has also been described. Extrarenal complications occur not only in the acute setting but may also be seen well after recovery from the acute phase of HUS. This review will focus on the extrarenal complications of STEC HUS. To date, management remains mainly supportive, and while there is no specific therapy for STEC HUS, supportive therapy has significantly reduced the mortality rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.